Catégorie : Substances psychédéliques et therapeutique

Psychedelics Promote Structural and Functional Neural Plasticity, Astral X Neural Plasticity, Alexandra C. Greb et al., 2018

Psychedelics Promote Structural and Functional Neural Plasticity Astral X Neural Plasticity, Alexandra C. Greb, Lindsay P. Cameron, Jonathan M. Wong, Eden V. Barragan, Paige C. Wilson, Kyle F. Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R. Padd, Whitney C. Duim, Megan Y. Dennis, A. Kimberley McAllister, Kassandra M. Ori-McKenney, John A. Gray and David E. Olson Experiment Findings, February 2018 https://www.researchgate.net/publication/331396378   SUMMARY Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast-acting antidepressant properties of the [...]

Lire la suite

Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities, Frederic Sampedro et al., 2017

Assessing the psychedelic “after-glow” in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. Ayahuasca post-acute effects Regular Research Article Frederic Sampedro, Mario de la Fuente Revenga, Marta Valle, Natalia Roberto, Elisabet Domínguez-Clavé, Matilde Elices, Luís Eduardo Luna, José Alexandre S. Crippa, Jaime E. C. Hallak, Draulio B. de Araujo, Pablo Friedlander, Steven A. Barker, Enrique Álvarez, Joaquim Soler, Juan C. Pascual, Amanda Feilding and Jordi Riba © The Author 2017. Published by Oxford University Press on behalf of CINP. The International Journal of Neuropsychopharmacology, 2017, 20, 9 DOI : 10.1093/ijnp/pyx036 Significance Statement Psychedelics are intriguing drugs that induce transient but intense [...]

Lire la suite

Four Weekly Ayahuasca Sessions Lead to Increases in “Acceptance” Capacities : A Comparison Study With a Standard 8-Week Mindfulness Training Program, Joaquim Soler et al., 2018,

Four Weekly Ayahuasca Sessions Lead to Increases in “Acceptance” Capacities : A Comparison Study With a Standard 8-Week Mindfulness Training Program Joaquim Soler, Matilde Elices, Elisabeth Dominguez-Clavé, Juan C. Pascual, Amanda Feilding, Mayte Navarro-Gil, Javier García-Campayo and Jordi Riba Frontiers in Pharmacology, 2018, 9, 224. doi: 10.3389/fphar.2018.00224   Background : The therapeutic effects of the Amazonian plant tea ayahuasca may relate to its ability to enhance mindfulness capacities. Ayahuasca induces a modified state of awareness through the combined action of its active principles: the psychedelic N,N-dimethyltryptamine (DMT) and a series of centrally acting b-carbolines, mainly harmine and tetrahydroharmine. To better understand the therapeutic potential of [...]

Lire la suite

Ketamine and Other NMDA Antagonists : Early Clinical Trials and Possible Mechanisms in Depression, D. Jeffrey Newport et al., 2015

Ketamine and Other NMDA Antagonists : Early Clinical Trials and Possible Mechanisms in Depression D. Jeffrey Newport, M.D., M.S., M.Div., Linda L. Carpenter, M.D., William M. McDonald, M.D., James B. Potash, M.D., M.P.H., Mauricio Tohen, M.D., Dr.P.H., M.B.A., Charles B. Nemeroff, M.D., Ph.D., The APA Council of Research Task Force on Novel Biomarkers and Treatments American Journal of Psychiatry, 2015, 172, 950–966 doi: 10.1176/appi.ajp.2015.15040465     Objective : The authors conducted a systematic review and meta-analysis of ketamine and other N-methyl-D-aspartate (NMDA) receptor antagonists in the treatment of major depression. Method : Searches of MEDLINE, PsycINFO, and other databases were conducted for placebo-controlled, double-blind, randomized clinical trials [...]

Lire la suite

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. A Randomized Clinical Trial, Ella J. Daly et al., 2019

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression. A Randomized Clinical Trial Ella J. Daly, MD; Madhukar H. Trivedi, MD; Adam Janik, MD; Honglan Li, MD, PhD; Yun Zhang, PhD; Xiang Li, PhD; Rosanne Lane, MAS; Pilar Lim, PhD; Anna R. Duca, BSN; David Hough, MD; Michael E. Thase, MD; John Zajecka, MD; Andrew Winokur,MD, PhD; Ilona Divacka, MBA, MD; Andrea Fagiolini, MD; Wiesław J. Cubała, MD, PhD; István Bitter,MD, PhD; Pierre Blier,MD, PhD; Richard C. Shelton, MD; Patricio Molero,MD, PhD; Husseini Manji, MD;Wayne C. Drevets, MD; Jaskaran B. Singh, MD JAMA Psychiatry, [...]

Lire la suite

Lysergic acid diethylamide (LSD) for alcoholism : meta-analysis of randomized controlled trials, Teri S Krebs and Pål-Ørjan Johansen, 2012

Lysergic acid diethylamide (LSD) for alcoholism : meta-analysis of randomized controlled trials Teri S Krebs and Pål-Ørjan Johansen Journal of Psychopharmacology, 2012, 1–9 DOI: 10.1177/0269881112439253 jop.sagepub.com   Abstract Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse variance, random effects model. We identified six eligible trials, including 536 participants. There was evidence for a beneficial effect of LSD [...]

Lire la suite

Cessation and reduction in alcohol consumption and misuse after psychedelic use, Albert Garcia-Romeu et al., 2019

Cessation and reduction in alcohol consumption and misuse after psychedelic use Albert Garcia-Romeu, Alan K Davis, Fire Erowid, Earth Erowid, Roland R Griffiths and Matthew W Johnson Journal of Psychopharmacology, 2019, 1–14 DOI: 10.1177/0269881119845793 journals.sagepub.com/home/jop   Abstract Background : Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant effects for LSD efficacy compared to control conditions. Clinical studies suggest potential anti-addiction effects of LSD and mechanistically-related classic psychedelics for alcohol and other substance use disorders. Aims : To supplement clinical studies, reports of psychedelic use in naturalistic settings can provide further data regarding potential effects of psychedelics on alcohol use. Methods [...]

Lire la suite

Current perspectives on psychedelic therapy : use of serotonergic hallucinogens in clinical interventions, Albert Garcia-Romeu and William A. Richards, 2018

Current perspectives on psychedelic therapy : use of serotonergic hallucinogens in clinical interventions Albert Garcia-Romeu and William A. Richards Department of Psychiatry & Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA INTERNATIONAL REVIEW OF PSYCHIATRY, 2018 https://doi.org/10.1080/09540261.2018.1486289   ABSTRACT Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but their administration as part of a structured therapeutic intervention is still a relatively novel practice within Western medical and psychological frameworks. In the mid-20th century, considerable advances were made in developing therapeutic approaches integrating administration of low (psycholytic) and high (psychedelic) doses of serotonergic hallucinogens for treatment [...]

Lire la suite

A Contemporary History of Ibogaine in the United States and Europe, Kenneth R. Alper et al., 2001

A Contemporary History of Ibogaine in the United States and Europe THE ALKALOIDS, 2001, Vol.56, Chapitre 14 Copyright © 2001 by Academic Press 0099-9598/01 Kenneth R. Alper, Dana Beal & Charles D. Kaplan   I. Introduction In 1995, Dr. Curtis Wright, then the U.S. Food and Drug Administration (FDA) ibogaine project officer, wrote “What’s clear is that a significant portion of the public we serve believes the drug merits investigation” (1). Wright’s statement intimates a relationship of public opinion to regulatory scientific policy. The statement was made at a time when the FDA, partly in response to highly motivated and organized public advocacy, was modifying its drug [...]

Lire la suite

LSD helps to treat alcoholism, Arran Frood, Nature, 2012

LSD helps to treat alcoholism Retrospective analysis shows hallucinogenic drug helped problem drinkers. Arran Frood Nature, 09 March 2012 doi : 10.1038/nature.2012.10200   Rights & Permissions DEA/Science Faction/Corbis An analysis of old studies suggests LSD may have a role to play in treating alcoholism. The powerful hallucinogen LSD (lysergic acid diethylamide) has potential as a treatment for alcoholism, according to a retrospective analysis of studies published in the late 1960s and early 1970s. The study1, by neuroscientist Teri Krebs and clinical psychologist Pål-Ørjan Johansen of the Norwegian University of Science and Technology in Trondheim, is the first-ever quantitative meta-analysis of LSD–alcoholism clinical trials. The researchers sifted through [...]

Lire la suite